EU, IAVI Strengthen Joint Efforts to Develop and Distribute AIDS Vaccines

Apr 26, 2001, 01:00 ET from European Union and International AIDS Vaccine Initiative

    ABUJA, Nigeria, April 26 /PRNewswire/ -- The European Union (EU) and the
 International AIDS Vaccine Initiative (IAVI) are strengthening their joint
 efforts to promote the accelerated development of preventive vaccines for AIDS
 and assure they are available in developing countries as rapidly as possible.
 The announcement was made as heads of state gather in Abuja, Nigeria, for the
 African Summit on HIV/AIDS, Tuberculosis and Other Related Infectious
 Diseases.
 
     Following is the text of the joint EU-IAVI statement:
 
     Joint statement by the European Union and the International AIDS Vaccine
 Initiative At the occasion of the African summit on HIV/AIDS, tuberculosis and
 other infectious diseases 26 April 2001, Aubja, Nigeria
 
     The European Union (EU) and the International AIDS Vaccine Initiative
 (IAVI), on the occasion of this important gathering of African and
 international leaders, wish to announce the strengthening of joint EU-IAVI
 efforts to confront the AIDS pandemic in developing countries.
     The EU and IAVI consider that this summit will substantially raise global
 awareness on the need for AIDS vaccines and that the event offers an
 opportunity to broaden our alliances in support of the development of an AIDS
 vaccine for developing countries.
     Preventative AIDS vaccines provide the best hope for ending the AIDS
 pandemic in the long term. The strengthening of the EU-IAVI partnership
 reflects our common goal: to promote the accelerated development of AIDS
 vaccines and to ensure that they are available to people in developing
 countries as rapidly as possible.
     Investment and promotion of new international public goods--such as AIDS
 vaccines--are an integral part of a balanced approach as outlined in the
 European Union's new Policy and Programme for Action on "Accelerated Action on
 Major Communicable Diseases within the context of poverty reduction." This new
 policy defines a comprehensive approach to increase the impact of existing
 interventions, increase the affordability of key pharmaceuticals and to
 accelerate investment in new R&D for HIV/AIDS, TB and malaria. The EU and IAVI
 will collaborate closely in accelerating the development and availability of
 AIDS vaccines for developing countries. To this end the EC and IAVI have
 agreed to strengthen their operational partnership, the first steps of which
 will include the following:
 
     -- IAVI will formally join in the work of the EC AIDS Vaccine Task Team
        and provide technical input to the further development of the EC's AIDS
        vaccine strategy. This will include collaboration on regulatory issues
        and incentives to develop and ensure access to AIDS vaccines in
        developing countries.
 
     -- IAVI and the EC will work together to accelerate R&D programs for AIDS
        vaccines and to organize effective public/private support to clinical
        trial platforms.
 
     -- IAVI and the EC share concerns on community involvement and the
        safeguarding of ethical standards during trials. They will work
        together with developing countries to build capacity and ensure
        adequate vaccine preparedness in advance of large-scale clinical
        trials.
 
     -- The EC and IAVI will build upon, and expand, existing collaborations
        such as the joint project in South Africa. The integration of IAVI
        technical expertise and on the ground experience into the EU country
        programs will bring added benefits to both partners.
 
     -- The EC and IAVI have common partners in several EU Member States, UN
        organizations and developing countries and will work together with
        these various partners to promote and develop AIDS vaccines for
        developing countries.
 
     About the African AIDS summit
     The African Summit on HIV/AIDS, Tuberculosis and Other Related Infectious
 Diseases is being held 24-27 April in Abuja, Nigeria, and is sponsored by
 the Organization for African Unity (OAU) and the Joint United Nations
 Programme on HIV/AIDS (UNAIDS).
 
     About IAVI
     The International AIDS Vaccine Initiative (IAVI) is an international
 nonprofit scientific organization founded in 1996 whose mission is to ensure
 the development of safe, effective and accessible preventive HIV vaccines for
 use throughout the world. IAVI's work focuses on four areas: creating global
 demand for AIDS vaccines through advocacy and education; accelerating
 scientific progress; encouraging industrial involvement in AIDS vaccine
 development; and assuring global access. Two IAVI-sponsored vaccines developed
 for Africa are already in clinical trials, and IAVI is committed to moving
 other candidate vaccines for developing countries into clinical trials as
 quickly as possible. IAVI is a UNAIDS collaborating center. Its major donors
 include the Bill & Melinda Gates Foundation, the Rockefeller Foundation, the
 Sloan Foundation and the Starr Foundation; the governments of the United
 Kingdom, the United States, the Netherlands, Canada and Ireland; and the World
 Bank. For more information, visit http://www.iavi.org.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X58281587
 
 

SOURCE European Union and International AIDS Vaccine Initiative
    ABUJA, Nigeria, April 26 /PRNewswire/ -- The European Union (EU) and the
 International AIDS Vaccine Initiative (IAVI) are strengthening their joint
 efforts to promote the accelerated development of preventive vaccines for AIDS
 and assure they are available in developing countries as rapidly as possible.
 The announcement was made as heads of state gather in Abuja, Nigeria, for the
 African Summit on HIV/AIDS, Tuberculosis and Other Related Infectious
 Diseases.
 
     Following is the text of the joint EU-IAVI statement:
 
     Joint statement by the European Union and the International AIDS Vaccine
 Initiative At the occasion of the African summit on HIV/AIDS, tuberculosis and
 other infectious diseases 26 April 2001, Aubja, Nigeria
 
     The European Union (EU) and the International AIDS Vaccine Initiative
 (IAVI), on the occasion of this important gathering of African and
 international leaders, wish to announce the strengthening of joint EU-IAVI
 efforts to confront the AIDS pandemic in developing countries.
     The EU and IAVI consider that this summit will substantially raise global
 awareness on the need for AIDS vaccines and that the event offers an
 opportunity to broaden our alliances in support of the development of an AIDS
 vaccine for developing countries.
     Preventative AIDS vaccines provide the best hope for ending the AIDS
 pandemic in the long term. The strengthening of the EU-IAVI partnership
 reflects our common goal: to promote the accelerated development of AIDS
 vaccines and to ensure that they are available to people in developing
 countries as rapidly as possible.
     Investment and promotion of new international public goods--such as AIDS
 vaccines--are an integral part of a balanced approach as outlined in the
 European Union's new Policy and Programme for Action on "Accelerated Action on
 Major Communicable Diseases within the context of poverty reduction." This new
 policy defines a comprehensive approach to increase the impact of existing
 interventions, increase the affordability of key pharmaceuticals and to
 accelerate investment in new R&D for HIV/AIDS, TB and malaria. The EU and IAVI
 will collaborate closely in accelerating the development and availability of
 AIDS vaccines for developing countries. To this end the EC and IAVI have
 agreed to strengthen their operational partnership, the first steps of which
 will include the following:
 
     -- IAVI will formally join in the work of the EC AIDS Vaccine Task Team
        and provide technical input to the further development of the EC's AIDS
        vaccine strategy. This will include collaboration on regulatory issues
        and incentives to develop and ensure access to AIDS vaccines in
        developing countries.
 
     -- IAVI and the EC will work together to accelerate R&D programs for AIDS
        vaccines and to organize effective public/private support to clinical
        trial platforms.
 
     -- IAVI and the EC share concerns on community involvement and the
        safeguarding of ethical standards during trials. They will work
        together with developing countries to build capacity and ensure
        adequate vaccine preparedness in advance of large-scale clinical
        trials.
 
     -- The EC and IAVI will build upon, and expand, existing collaborations
        such as the joint project in South Africa. The integration of IAVI
        technical expertise and on the ground experience into the EU country
        programs will bring added benefits to both partners.
 
     -- The EC and IAVI have common partners in several EU Member States, UN
        organizations and developing countries and will work together with
        these various partners to promote and develop AIDS vaccines for
        developing countries.
 
     About the African AIDS summit
     The African Summit on HIV/AIDS, Tuberculosis and Other Related Infectious
 Diseases is being held 24-27 April in Abuja, Nigeria, and is sponsored by
 the Organization for African Unity (OAU) and the Joint United Nations
 Programme on HIV/AIDS (UNAIDS).
 
     About IAVI
     The International AIDS Vaccine Initiative (IAVI) is an international
 nonprofit scientific organization founded in 1996 whose mission is to ensure
 the development of safe, effective and accessible preventive HIV vaccines for
 use throughout the world. IAVI's work focuses on four areas: creating global
 demand for AIDS vaccines through advocacy and education; accelerating
 scientific progress; encouraging industrial involvement in AIDS vaccine
 development; and assuring global access. Two IAVI-sponsored vaccines developed
 for Africa are already in clinical trials, and IAVI is committed to moving
 other candidate vaccines for developing countries into clinical trials as
 quickly as possible. IAVI is a UNAIDS collaborating center. Its major donors
 include the Bill & Melinda Gates Foundation, the Rockefeller Foundation, the
 Sloan Foundation and the Starr Foundation; the governments of the United
 Kingdom, the United States, the Netherlands, Canada and Ireland; and the World
 Bank. For more information, visit http://www.iavi.org.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X58281587
 
 SOURCE  European Union and International AIDS Vaccine Initiative